Stock listing

OTC:IDXG Interpace Biosciences, Inc. Stock

Follow Interpace Biosciences, Inc. into a list and get an email when it puts out news.

Share price · OTC:IDXG

$4.50 USD -0.93 (-17.1%)

Close on Nov 20, 2026

Past year +1,375% · daily closes, Jul 17, 2026 – Nov 20, 2026, adjusted for splits
Day range
$4.44 – $4.60 USDNov 20, 2026
Volume
2,800 sharesNov 20, 2026
Market cap
$26.56M USDAt the close on Nov 20, 2026 · price × 5.90M shares outstanding
Traded on an average day
$12,365 USDMedian day 700 shares · 10 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:IDXG · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$4.50-0.93-17.1%$4.60$4.60$4.442,800
$5.43-0.57-9.5%$5.40$5.45$5.401,760
$6.00-0.20-3.2%$6.05$6.05$6.00200
$6.20+0.15+2.5%$6.20$6.20$6.20327
$6.05-0.20-3.2%$6.05$6.05$6.051
$6.25+0.05+0.8%$6.20$6.25$6.20600
$6.200.000.0%$6.60$6.60$6.20101
$6.20-0.80-11.4%$6.20$6.20$6.205
$7.000.000.0%$7.00$7.00$7.00100
$7.00+1.28+22.4%$5.74$7.00$5.741,207
$5.72+0.37+6.9%$5.50$5.72$5.50830
$5.35-0.37-6.5%$5.35$5.35$5.351
$5.72+0.77+15.6%$5.00$5.72$5.003,405
$4.95-0.55-10.0%$5.45$5.45$4.951,500
$5.50-1.00-15.4%$6.00$6.00$5.502,601
$6.50+1.10+20.4%$5.80$6.50$5.802,750
$5.40+0.35+6.9%$5.40$5.40$5.40100
$5.05-0.05-1.0%$5.05$5.25$5.05522
$5.10+0.10+2.0%$5.10$5.10$5.10500
$5.00-0.15-2.9%$5.09$5.29$5.002,917
$5.15-0.12-2.3%$5.20$5.20$5.051,800
$5.27-0.248-4.5%$5.38$5.39$5.273,300
$5.518-0.382-6.5%$5.518$5.518$5.518300
$5.90-0.23-3.8%$6.073$6.13$5.903,700
$6.13+0.13+2.2%$5.97$6.13$5.856,300
$6.000.000.0%$6.00$6.00$6.00400
$6.000.000.0%$6.00$6.00$6.000
$6.00-0.025-0.4%$6.32$6.32$6.00400
$6.0250.000.0%$6.025$6.025$6.0250
$6.0250.000.0%$6.025$6.025$6.0250
$6.025-0.365-5.7%$6.15$6.15$6.00800
$6.390.000.0%$6.39$6.39$6.390
$6.39-0.03-0.5%$6.39$6.39$6.39100
$6.420.000.0%$6.42$6.42$6.420
$6.42+0.01+0.2%$6.42$6.42$6.42300
$6.41-0.06-0.9%$6.25$6.425$6.014,700
$6.470.000.0%$6.47$6.47$6.470
$6.470.000.0%$6.47$6.47$6.470
$6.47+0.02+0.3%$6.55$6.55$6.451,500
$6.450.000.0%$6.45$6.45$6.450
$6.450.000.0%$6.65$6.65$6.45700
$6.450.000.0%$6.45$6.45$6.45200
$6.45-0.05-0.8%$6.53$6.53$6.45500
$6.50+0.20+3.2%$6.45$6.50$6.45700
$6.30-0.20-3.1%$6.45$6.45$5.9735,900
$6.50-0.07-1.1%$6.50$6.60$6.508,200
$6.57+0.07+1.1%$6.55$6.57$6.552,800
$6.50-0.413-6.0%$6.80$6.80$6.50300
$6.9130.000.0%$6.913$6.913$6.9130
$6.913+0.403+6.2%$6.69$6.913$6.503,300
$6.51-0.47-6.7%$6.92$6.98$6.459,500
$6.98-0.02-0.3%$7.058$7.058$6.985,300
$7.00-0.57-7.5%$7.47$7.47$6.8023,800
$7.57-0.048-0.6%$7.59$7.59$7.575,500
$7.618+7.328+2526.9%$6.50$7.80$6.502,500
$0.290.000.0%$0.29$0.29$0.290
$0.29+0.006+2.1%$0.284$0.314$0.2847,100
$0.284-0.002-0.7%$0.282$0.29$0.2626,500
$0.286-0.019-6.1%$0.288$0.29$0.2852,000
$0.305-0.017-5.4%$0.302$0.309$0.2829,800
$0.322+0.008+2.5%$0.316$0.326$0.31629,800

Splits

2 splits since 2016 · OTC:IDXG · every price before a split is adjusted for it

DayRatioWhat
1-for-10Consolidation
1-for-10Consolidation
Ticker
OTC:IDXG
Asset type
Stock
Sector
Health care
Industry
Diagnostics & research services
Exchange
OTC
Currency
USD

What changed lately

Latest news

All Interpace Biosciences, Inc. news

Interpace Biosciences, Inc. on 6ix

Sector
Health care
Industry
Diagnostics & research services
News releases
2 in the last 12 months · 2 in all · newest Nov 16, 2026 · oldest 2026

Valuation

P/E 1.2× against a median of 20.0×: the lowest of 3 Diagnostics & research services companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$23.63M USD
P/E
1.2×
EV/sales
0.6×
EV/EBITDA
21.0×
Price/book
1.1×
Gross margin
65.6%
Operating margin
1.7%
Net margin
58.1%
Debt to equity
0.0×
Beta vs S&P 500
-0.33

Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Interpace Biosciences, Inc. · OTC:IDXGUS$26.56MUS$23.63M1.2×0.6×21.0×1.1×58.1%0.0×-0.33
Abingdon Health PLC · LSE:ABDXUS$28.10MUS$26.11Mn/a1.8×n/a3.5×−19.4%0.2×n/a
MedMira Inc. · TSXV:MIRUS$26.91MUS$27.23Mn/a105×n/an/a−808.2%n/a0.29
BIOQUAL, Inc. · OTC:BIOQUS$26.83MUS$42.28Mn/a1.1×n/a0.8×−11.0%1.0×-0.01
Ikonisys SA · EURONEXT:ALIKOUS$26.75MUS$31.11Mn/a20.4×n/a1.3×−302.8%0.3×n/a
Microbix Biosystems Inc. · TSX:MBXUS$26.27MUS$25.96Mn/a2.4×n/a1.6×−31.7%0.3×0.03
Bioptic Inc. · TPEX:6850US$26.10MUS$22.55Mn/an/an/a2.0×n/a0.2×n/a
genOway SA · EURONEXT:ALGENUS$25.86MUS$38.95M25.4×1.7×8.7×1.1×4.4%0.7×n/a
Orientbio, Inc. · KRX:002630US$25.17M−US$3.29M14.6×−0.1×−0.8×0.5×8.1%0.0×n/a
Genesystem Co., Ltd. · KRX:363250US$24.68MUS$22.48Mn/a29.8×n/a2.8×n/a0.2×n/a
Clever Culture Systems Limited · ASX:CC5US$24.56MUS$25.41Mn/a8.3×n/a4.9×−48.4%0.4×n/a
Median of the othersUS$26.18MUS$26.04M20.0×2.4×3.9×1.6×−25.5%0.3×0.03

Team and board

Officers

OfficerRole
Thomas BurnellPresident, CEO, Chairman of the Board
Christopher McCarthyChief Financial Officer and Chief Operating Officer
Interpace BiosciencesInvestor Relations
Nicole MassollChief Medical Officer
Syd FinkelsteinChief Pathology Officer

Board

DirectorRole
Thomas BurnellPresident, CEO, Chairman of the Board
Joseph KeeganDirector
Ron RoccaDirector
Stephen J. SullivanDirector
Vijay AggarwalDirector

Events

QuarterResults
Q1 2026May 7, 2026
Q4 2025Mar 5, 2026
Q3 2025Nov 13, 2025
Q2 2025Aug 7, 2025
Q1 2025May 19, 2025
Q4 2024Mar 31, 2025
Q3 2024Nov 4, 2024
Q2 2024Aug 2, 2024
Q1 2024May 9, 2024 · After close
Q4 2023Mar 7, 2024
All 20 quarters
QuarterResults
Q3 2023Nov 8, 2023 · After close
Q2 2023Aug 9, 2023 · After close
Q1 2023May 12, 2023 · After close
Q4 2022Mar 27, 2023 · After close
Q3 2022Nov 14, 2022 · After close
Q2 2022Aug 15, 2022 · After close
Q1 2022May 16, 2022 · After close
Q4 2021Mar 31, 2022 · After close
Quarter to Sep 30, 2021Nov 10, 2021 · After close
Quarter to Jun 30, 2021Aug 10, 2021 · After close

Open Events

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue38.7M46.9M40.0M5.68M8.20M32.4M24.2M21.9M15.9M13.1M
Cost of revenue14.6M17.0M15.0M13.6M14.3M21.7M15.9M10.2M7.36M6.64M
Gross profit24.1M29.9M25.1M18.2M18.8M10.7M8.33M11.7M8.54M6.44M
Research and development642.0K676.0K636.0K703.0K1.49M2.79M2.81M2.12M1.46M1.65M
Operating income4.08M8.11M3.96M-3.62M-6.34M-26.1M-26.4M-12.6M-6.29M-6.44M
Depreciation and amortization425.0K300.0K1.03M2.56M5.37M5.50M4.52M3.80M3.69M4.48M
EBITDA4.51M8.41M4.98M-1.06M-962.0K-20.6M-21.9M-8.83M-2.60M-1.96M
Interest expense549.0K440.0K331.0K433.0K2.14M
Income before tax3.77M6.95M2.28M-5.84M-7.74M-26.1M-26.7M-12.7M-13.1M-8.57M
Income tax-21.2M4.00K17.0K29.0K-705.0K53.0K-28.0K18.0K-395.0K-162.0K
Net income24.6M6.70M1.95M-22.0M-14.9M-26.5M-26.7M-12.7M12.6M-22.0M
Earnings per share, basic5.551.420.45-5.18-3.61-7.32-7.25-4.52-7.96-120.90
Earnings per share, diluted0.890.400.45-5.18-3.61-7.32-7.25-4.52-7.96-120.90

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents2.50M1.46M3.50M4.83M2.67M2.77M2.32M6.07M15.2M602.0K
Receivables5.65M8.54M5.08M5.03M4.67M8.03M10.3M9.48M3.44M2.21M
Inventory1.11M1.21M1.23M1.22M825.0K2.05M1.82M
Current assets9.90M11.8M10.4M12.2M12.2M14.1M16.5M17.7M19.8M4.24M
Property, plant and equipment1.42M1.36M790.0K480.0K317.0K7.35M6.81M837.0K654.0K929.0K
Goodwill8.43M8.43M8.43M
Total assets33.8M14.8M13.1M16.0M38.4M45.7M51.5M31.1M36.6M25.1M
Accounts payable983.0K1.66M1.54M1.05M1.37M4.51M4.71M1.06M391.0K2.33M
Current liabilities5.10M10.6M11.4M14.3M15.7M18.2M17.3M8.67M8.09M16.2M
Long-term debt1.85M520.0K3.68M2.71M7.91M
Total debt578.0K762.0K1.20M1.50M7.91M
Total liabilities11.5M17.0M22.1M32.5M34.3M28.2M29.8M15.7M13.7M35.2M
Shareholders' equity22.4M-2.22M-55.5M-58.1M-42.4M-29.1M-4.48M15.4M22.9M-10.1M
Shares outstanding885.7K4.41M4.35M4.30M4.20M4.06M3.92M2.87M27.8M2.18M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations5.83M4.65M3.79M-7.69M-8.72M-14.0M-19.0M-8.67M-15.3M-7.61M
Capital spending-356.0K-876.0K-470.0K-322.0K-354.0K-1.57M-131.0K-449.0K-29.0K
Free cash flow5.47M3.77M3.32M-8.01M-9.07M-15.6M-19.1M-9.12M-15.3M
Cash from investing-356.0K-876.0K-87.0K6.21M-315.0K-1.57M-13.9M-449.0K-29.0K
Cash from financing-4.43M-5.81M-5.03M3.00M8.98M16.6M29.2M-9.00K29.9M-101.0K
Change in cash1.04M-2.04M-1.33M1.51M-58.0K1.05M-3.75M-9.13M14.6M-7.71M

Open Financials

Filings

FilingDateTypeFiled with
RW · Request to withdraw a registrationNov 18, 2026Other filingsSEC
8-K · Current reportNov 17, 2026ResultsSEC
10-Q · Quarterly reportNov 16, 2026Quarterly reportSEC
CERT · Exchange's certificate of listingNov 5, 2026Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeNov 5, 2026Other filingsSEC
S-1/A · Registration statement, amendedOct 30, 2026Offer documentSEC
FWP · Free writing prospectusOct 15, 2026Offer documentSEC
8-K · Current reportOct 15, 2026ResultsSEC
S-1/A · Registration statement, amendedSep 30, 2026Offer documentSEC
S-1 · Registration statementSep 24, 2026Offer documentSEC
Show 200 filings
FilingDateTypeFiled with
S-8 · Registration statement for employee plansSep 17, 2026Offer documentSEC
8-K · Current reportAug 27, 2026Current reportSEC
8-K/A · Current report, amendedAug 26, 2026Management or board changeSEC
8-K · Current reportAug 20, 2026Meeting outcomeSEC
4 · Change in ownershipAug 20, 2026Insider tradeSEC
4 · Change in ownershipAug 20, 2026Insider tradeSEC
4 · Change in ownershipAug 20, 2026Insider tradeSEC
4 · Change in ownershipAug 20, 2026Insider tradeSEC
4 · Change in ownershipAug 20, 2026Insider tradeSEC
4 · Change in ownershipAug 20, 2026Insider tradeSEC
8-K · Current reportAug 12, 2026ResultsSEC
10-Q · Quarterly reportAug 10, 2026Quarterly reportSEC
DRS · Draft registration statementJul 22, 2026Offer documentSEC
DEFA14A · Additional proxy materialJul 7, 2026Meeting noticeSEC
DEF 14A · Proxy statementJul 7, 2026Meeting noticeSEC
PREM14AJun 24, 2026Other filingsSEC
PRE 14A · Preliminary proxy statementJun 23, 2026Meeting noticeSEC
8-K · Current reportMay 14, 2026ResultsSEC
10-Q · Quarterly reportMay 12, 2026Quarterly reportSEC
10-K/A · Annual report, amendedApr 30, 2026Annual reportSEC
8-K · Current reportApr 1, 2026ResultsSEC
10-K · Annual reportMar 30, 2026Annual reportSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
8-K · Current reportJan 20, 2026ResultsSEC
8-K · Current reportDec 3, 2025Current reportSEC
8-K · Current reportNov 12, 2025ResultsSEC
10-Q · Quarterly reportNov 12, 2025Quarterly reportSEC
8-K · Current reportAug 8, 2025ResultsSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
10-Q · Quarterly reportMay 8, 2025Quarterly reportSEC
8-K · Current reportMay 8, 2025ResultsSEC
8-K · Current reportApr 30, 2025Current reportSEC
10-K/A · Annual report, amendedApr 28, 2025Annual reportSEC
4 · Change in ownershipApr 25, 2025Insider tradeSEC
10-K · Annual reportMar 31, 2025Annual reportSEC
8-K · Current reportMar 6, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
8-K · Current reportJan 27, 2025Current reportSEC
8-K · Current reportJan 21, 2025Material contractSEC
8-K · Current reportJan 10, 2025Current reportSEC
8-K · Current reportNov 13, 2024Meeting outcomeSEC
10-Q · Quarterly reportNov 8, 2024Quarterly reportSEC
8-K · Current reportNov 6, 2024ResultsSEC
SC 13D/A · Big-stake notice, amendedOct 16, 2024Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedOct 16, 2024Big-stake noticeSEC
DOct 16, 2024Other filingsSEC
4 · Change in ownershipOct 15, 2024Insider tradeSEC
4 · Change in ownershipOct 15, 2024Insider tradeSEC
8-K · Current reportOct 15, 2024Material contractSEC
DEFA14A · Additional proxy materialSep 20, 2024Meeting noticeSEC
DEF 14A · Proxy statementSep 20, 2024Meeting noticeSEC
10-Q · Quarterly reportAug 8, 2024Quarterly reportSEC
8-K · Current reportAug 2, 2024ResultsSEC
8-K · Current reportMay 9, 2024ResultsSEC
10-Q · Quarterly reportMay 9, 2024Quarterly reportSEC
10-K/A · Annual report, amendedApr 26, 2024Annual reportSEC
10-K · Annual reportApr 1, 2024Annual reportSEC
8-K · Current reportMar 12, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedFeb 12, 2024Big-stake noticeSEC
4 · Change in ownershipFeb 6, 2024Insider tradeSEC
8-K · Current reportDec 12, 2023Management or board changeSEC
8-K · Current reportNov 16, 2023Management or board changeSEC
8-K · Current reportNov 8, 2023ResultsSEC
10-Q · Quarterly reportNov 8, 2023Quarterly reportSEC
8-K · Current reportOct 27, 2023Material contractSEC
DEFA14A · Additional proxy materialSep 22, 2023Meeting noticeSEC
DEF 14A · Proxy statementSep 22, 2023Meeting noticeSEC
8-K · Current reportAug 9, 2023ResultsSEC
10-Q · Quarterly reportAug 9, 2023Quarterly reportSEC
8-K · Current reportAug 1, 2023Management or board changeSEC
4 · Change in ownershipAug 1, 2023Insider tradeSEC
8-K · Current reportMay 12, 2023ResultsSEC
10-Q · Quarterly reportMay 12, 2023Quarterly reportSEC
3 · Initial statement of ownershipMay 3, 2023Insider tradeSEC
10-K/A · Annual report, amendedApr 28, 2023Annual reportSEC
8-K · Current reportApr 24, 2023Management or board changeSEC
8-K · Current reportMar 27, 2023ResultsSEC
10-K · Annual reportMar 27, 2023Annual reportSEC
SC 13G/A · Big-stake notice, amendedFeb 10, 2023Big-stake noticeSEC
8-K · Current reportNov 15, 2022Management or board changeSEC
10-Q · Quarterly reportNov 14, 2022Quarterly reportSEC
8-K · Current reportNov 14, 2022ResultsSEC
8-K · Current reportNov 4, 2022Material contractSEC
8-K · Current reportOct 4, 2022Management or board changeSEC
DEFA14A · Additional proxy materialSep 20, 2022Meeting noticeSEC
DEF 14A · Proxy statementSep 20, 2022Meeting noticeSEC
PRE 14A · Preliminary proxy statementSep 9, 2022Meeting noticeSEC
8-K · Current reportSep 7, 2022Acquisition or disposalSEC
8-K · Current reportAug 15, 2022ResultsSEC
10-Q · Quarterly reportAug 15, 2022Quarterly reportSEC
RW · Request to withdraw a registrationJun 16, 2022Other filingsSEC
10-Q · Quarterly reportMay 16, 2022Quarterly reportSEC
8-K · Current reportMay 16, 2022ResultsSEC
8-K · Current reportMay 10, 2022Material contractSEC
10-K/A · Annual report, amendedApr 29, 2022Annual reportSEC
8-K · Current reportApr 14, 2022Current reportSEC
8-K · Current reportMar 31, 2022ResultsSEC
10-K · Annual reportMar 31, 2022Annual reportSEC
SC 13G · Big-stake noticeFeb 10, 2022Big-stake noticeSEC
4 · Change in ownershipFeb 2, 2022Insider tradeSEC
3 · Initial statement of ownershipFeb 2, 2022Insider tradeSEC
SC 13D/A · Big-stake notice, amendedFeb 1, 2022Big-stake noticeSEC
8-K · Current reportJan 28, 2022Current reportSEC
8-K · Current reportJan 27, 2022Material contractSEC
SC 13D/A · Big-stake notice, amendedJan 13, 2022Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveJan 13, 2022Other filingsSEC
424B4 · ProspectusJan 12, 2022Offer documentSEC
POS EXJan 12, 2022Other filingsSEC
CORRESP · Letter to the SECJan 10, 2022Other filingsSEC
S-1/A · Registration statement, amendedJan 7, 2022Offer documentSEC
S-1/A · Registration statement, amendedJan 3, 2022Offer documentSEC
UPLOAD · Letter from the SECDec 10, 2021Other filingsSEC
SC 13D/A · Big-stake notice, amendedDec 6, 2021Big-stake noticeSEC
S-1 · Registration statementDec 3, 2021Offer documentSEC
SC 13D/A · Big-stake notice, amendedNov 12, 2021Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedNov 12, 2021Big-stake noticeSEC
10-Q · Quarterly reportNov 10, 2021Quarterly reportSEC
8-K · Current reportNov 10, 2021ResultsSEC
8-K · Current reportNov 9, 2021Meeting outcomeSEC
8-K · Current reportNov 2, 2021Material contractSEC
8-K · Current reportOct 18, 2021Material contractSEC
8-K · Current reportOct 1, 2021Material contractSEC
DEF 14A · Proxy statementSep 27, 2021Meeting noticeSEC
8-K · Current reportAug 31, 2021Material contractSEC
UPLOAD · Letter from the SECAug 27, 2021Other filingsSEC
CORRESP · Letter to the SECAug 20, 2021Other filingsSEC
10-K/A · Annual report, amendedAug 20, 2021Annual reportSEC
10-K/A · Annual report, amendedAug 20, 2021Annual reportSEC
UPLOAD · Letter from the SECAug 11, 2021Other filingsSEC
10-Q · Quarterly reportAug 10, 2021Quarterly reportSEC
8-K · Current reportAug 10, 2021ResultsSEC
8-K · Current reportAug 6, 2021Current reportSEC
8-K · Current reportJun 29, 2021Material contractSEC
4 · Change in ownershipMay 25, 2021Insider tradeSEC
SC 13D/A · Big-stake notice, amendedMay 19, 2021Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedMay 18, 2021Big-stake noticeSEC
8-K · Current reportMay 11, 2021ResultsSEC
10-Q · Quarterly reportMay 11, 2021Quarterly reportSEC
10-K/A · Annual report, amendedApr 29, 2021Annual reportSEC
25-NSEApr 26, 2021Other filingsSEC
8-K · Current reportApr 5, 2021ResultsSEC
10-K · Annual reportApr 1, 2021Annual reportSEC
NT 10-K · Late filing noticeApr 1, 2021Explanation requestSEC
4 · Change in ownershipMar 12, 2021Insider tradeSEC
4 · Change in ownershipMar 1, 2021Insider tradeSEC
3 · Initial statement of ownershipMar 1, 2021Insider tradeSEC
SC 13D · Big-stake noticeMar 1, 2021Big-stake noticeSEC
8-K · Current reportFeb 24, 2021Current reportSEC
8-K · Current reportFeb 17, 2021Current reportSEC
SC 13G/A · Big-stake notice, amendedFeb 12, 2021Big-stake noticeSEC
8-K · Current reportFeb 4, 2021Management or board changeSEC
4 · Change in ownershipFeb 2, 2021Insider tradeSEC
S-8 · Registration statement for employee plansJan 29, 2021Offer documentSEC
SC 13D/A · Big-stake notice, amendedJan 21, 2021Big-stake noticeSEC
8-K · Current reportJan 20, 2021ResultsSEC
10-Q · Quarterly reportJan 19, 2021Quarterly reportSEC
10-Q/A · Quarterly report, amendedJan 19, 2021Quarterly reportSEC
10-Q/A · Quarterly report, amendedJan 19, 2021Quarterly reportSEC
10-K/A · Annual report, amendedJan 19, 2021Annual reportSEC
SC 13D/A · Big-stake notice, amendedJan 19, 2021Big-stake noticeSEC
8-K · Current reportJan 11, 2021Material contractSEC
8-K · Current reportDec 7, 2020Current reportSEC
4 · Change in ownershipDec 2, 2020Insider tradeSEC
4 · Change in ownershipDec 2, 2020Insider tradeSEC
3 · Initial statement of ownershipDec 2, 2020Insider tradeSEC
8-K · Current reportNov 25, 2020Management or board changeSEC
8-K · Current reportNov 19, 2020Current reportSEC
NT 10-Q · Late filing noticeNov 17, 2020Explanation requestSEC
8-K · Current reportOct 23, 2020Material contractSEC
8-K · Current reportOct 20, 2020ResultsSEC
10-Q · Quarterly reportOct 19, 2020Quarterly reportSEC
8-K · Current reportOct 14, 2020Current reportSEC
SC 13G · Big-stake noticeSep 11, 2020Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedAug 20, 2020Big-stake noticeSEC
8-K · Current reportAug 20, 2020Current reportSEC
NT 10-Q · Late filing noticeAug 14, 2020Explanation requestSEC
8-K · Current reportAug 14, 2020Current reportSEC
4 · Change in ownershipJul 31, 2020Insider tradeSEC
SC 13D · Big-stake noticeJul 24, 2020Big-stake noticeSEC
8-K · Current reportJul 14, 2020Management or board changeSEC
4 · Change in ownershipJul 13, 2020Insider tradeSEC
4 · Change in ownershipJul 10, 2020Insider tradeSEC
4 · Change in ownershipJul 10, 2020Insider tradeSEC
4 · Change in ownershipJul 10, 2020Insider tradeSEC
10-Q · Quarterly reportJun 26, 2020Quarterly reportSEC
8-K · Current reportJun 25, 2020ResultsSEC
DEF 14A · Proxy statementJun 9, 2020Meeting noticeSEC
8-K · Current reportJun 9, 2020Material contractSEC

This page holds 200 of 1,001 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Interpace Biosciences, Inc.’s releases · as of Nov 6, 2026

Common shares
5,901,964
Fully diluted
5,901,964

Fully diluted

LineSharesAs of
Common shares5,901,964Nov 6, 2026

Share count over time

CountShares
Nov 6, 20265,901,964

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Jack E Stover
Other companies: TransCode Therapeutics, Inc. (Director · Since at least Dec 19, 2025); Profusa, Inc. (Chief Executive Officer · Since at least Dec 20, 2021); Traws Pharma, Inc. (Director · Since at least May 18, 2016); PharmaCyte Biotech, Inc. (Director · Aug 15, 2022 – Aug 15, 2022 · Past); Antares Pharma Inc (President and CEO, Director · Jan 25, 2006 – May 14, 2008 · Past)
President and CEO, Director · Aug 3, 2005 – Mar 12, 2020 · Past
Graham G Miao
Other companies: AgroFresh Solutions Inc (Chief Financial Officer · Aug 30, 2018 – Mar 31, 2023 · Past); Pernix Therapeutics Holdings Inc (President and CFO, Director · Jul 26, 2016 – Aug 8, 2017 · Past); Delcath Systems, Inc. (Interim Co-CEO & Pres.EVP, CFO · Sep 26, 2011 – Nov 14, 2013 · Past)
CFO · Oct 20, 2014 – Dec 28, 2015 · Past
Joseph D. Keegan
Other companies: Bio-Techne Corp (Director · Since at least Oct 26, 2017); Stereotaxis, Inc. (Director · Feb 16, 2011 – May 24, 2016 · Past)
Director · Since at least Jan 1, 2016
Veronica Lubatkin
Other companies: Par Pharmaceutical Companies Inc (EVP, Chief Financial Officer · Jun 5, 2007 – Dec 31, 2008 · Past)
Director · Nov 18, 2008 – Jun 4, 2013 · Past
Christopher McCarthyChief Financial Officer and Chief Operating Officer · Since at least Apr 21, 2023
Edward ChanDirector · Jan 15, 2020 – Jan 15, 2020 · Past
Eric B LevDirector · Jul 15, 2019 – Jan 15, 2020 · Past
Felice Schnoll-SussmanDirector · Sep 12, 2017 – Mar 7, 2018 · Past
Gerald P BelleDirector · Jun 4, 2013 – Jun 3, 2015 · Past
Gregory RichardChief Commerical Officer · Sep 14, 2017 – Jan 22, 2020 · Past
All 22 people
PersonSeat
Howard DraznerSVP,Bus. Dev Medical Education · Apr 1, 2009 – Nov 29, 2010 · Past
Interpace BiosciencesInvestor Relations · Since at least Oct 15, 2026
Jeffrey Edward SmithVP of Corporate Development · Jan 30, 2012 – Nov 7, 2014 · Past
Jo Ann SaittaSVP and CIO, GM GROUP DCA · Jan 31, 2012 – Mar 1, 2013 · Past
Joseph I CurtiDirector · Jun 6, 2006 – Jun 4, 2009 · Past
Nicole MassollChief Medical Officer · Since at least Nov 5, 2026
Ron RoccaDirector · Since at least Nov 4, 2026
Stephen CotugnoExecutive Vice-President · Feb 15, 2006 – Feb 15, 2006 · Past
Stephen J. SullivanDirector · Since at least Jul 9, 2020
Syd FinkelsteinChief Pathology Officer · Since at least Nov 5, 2026
Thomas BurnellPresident, CEO, Chairman of the Board · Since at least Nov 5, 2026
Vijay AggarwalDirector · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Interpace Biosciences, Inc.